
Brenda Libby Coleman
Examiner (ID: 14798)
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 2611, 1611, 1202 |
| Total Applications | 3171 |
| Issued Applications | 1983 |
| Pending Applications | 480 |
| Abandoned Applications | 745 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17314389
[patent_doc_number] => 20210403437
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES
[patent_app_type] => utility
[patent_app_number] => 17/370643
[patent_app_country] => US
[patent_app_date] => 2021-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17370643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/370643 | Methods of selectively forming substituted pyrazines | Jul 7, 2021 | Issued |
Array
(
[id] => 17641914
[patent_doc_number] => 20220169652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/369507
[patent_app_country] => US
[patent_app_date] => 2021-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31168
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17369507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/369507 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Jul 6, 2021 | Issued |
Array
(
[id] => 20561603
[patent_doc_number] => 12564193
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-03
[patent_title] => Isoxazoline-substituted benzamide derivative, and preparation method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/003454
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6777
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003454
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/003454 | Isoxazoline-substituted benzamide derivative, and preparation method therefor and use thereof | Jun 30, 2021 | Issued |
Array
(
[id] => 17335940
[patent_doc_number] => 20220002271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => HETEROCYCLIC INHIBITORS OF PCSK9
[patent_app_type] => utility
[patent_app_number] => 17/363721
[patent_app_country] => US
[patent_app_date] => 2021-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363721
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/363721 | Heterocyclic inhibitors of PCSK9 | Jun 29, 2021 | Issued |
Array
(
[id] => 18597187
[patent_doc_number] => 20230271980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/003989
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10169
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 208
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18003989
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/003989 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | Jun 24, 2021 | Pending |
Array
(
[id] => 18413110
[patent_doc_number] => 11667643
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => RIP1K inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/358698
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21888
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 321
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17358698
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/358698 | RIP1K inhibitors | Jun 24, 2021 | Issued |
Array
(
[id] => 17299419
[patent_doc_number] => 20210395258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/356986
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356986
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/356986 | Heterocyclic derivatives as PI3K inhibitors | Jun 23, 2021 | Issued |
Array
(
[id] => 18955108
[patent_doc_number] => 20240043435
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => TYK-2 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/011590
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73500
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011590
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/011590 | TYK-2 INHIBITOR | Jun 20, 2021 | Pending |
Array
(
[id] => 18420063
[patent_doc_number] => 20230174524
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => AMINOPYRIDINE COMPOUND
[patent_app_type] => utility
[patent_app_number] => 18/000684
[patent_app_country] => US
[patent_app_date] => 2021-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4168
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000684
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000684 | AMINOPYRIDINE COMPOUND | Jun 16, 2021 | Pending |
Array
(
[id] => 17482086
[patent_doc_number] => 20220089590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 17/350183
[patent_app_country] => US
[patent_app_date] => 2021-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38794
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/350183 | Ether linked triazoles as NRF2 activators | Jun 16, 2021 | Issued |
Array
(
[id] => 17314435
[patent_doc_number] => 20210403483
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES
[patent_app_type] => utility
[patent_app_number] => 17/349140
[patent_app_country] => US
[patent_app_date] => 2021-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 587
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17349140
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/349140 | Poly heterocyclic conjugates and their pharmaceutical uses | Jun 15, 2021 | Issued |
Array
(
[id] => 18675028
[patent_doc_number] => 20230312577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => DUAL KINASE-BROMODOMAIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/000632
[patent_app_country] => US
[patent_app_date] => 2021-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76727
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 467
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000632
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000632 | DUAL KINASE-BROMODOMAIN INHIBITORS | Jun 3, 2021 | Abandoned |
Array
(
[id] => 18801270
[patent_doc_number] => 11834421
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
[patent_app_type] => utility
[patent_app_number] => 17/334517
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48671
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 312
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17334517
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/334517 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | May 27, 2021 | Issued |
Array
(
[id] => 17399515
[patent_doc_number] => 20220041605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
[patent_app_type] => utility
[patent_app_number] => 17/328618
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25919
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328618
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/328618 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | May 23, 2021 | Abandoned |
Array
(
[id] => 20491474
[patent_doc_number] => 12533329
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Compositions and methods of treatment with glutathione
[patent_app_type] => utility
[patent_app_number] => 17/999104
[patent_app_country] => US
[patent_app_date] => 2021-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2484
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999104
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999104 | Compositions and methods of treatment with glutathione | May 19, 2021 | Issued |
Array
(
[id] => 17243388
[patent_doc_number] => 20210363131
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => Antifibrotic Compounds And Related Methods
[patent_app_type] => utility
[patent_app_number] => 17/319812
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 420
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319812
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/319812 | Antifibrotic compounds and related methods | May 12, 2021 | Issued |
Array
(
[id] => 17258438
[patent_doc_number] => 20210371423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => Ibogaine-related compounds and corresponding methods
[patent_app_type] => utility
[patent_app_number] => 17/300293
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1757
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17300293
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/300293 | Ibogaine-related compounds and corresponding methods | May 12, 2021 | Issued |
Array
(
[id] => 17399457
[patent_doc_number] => 20220041547
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection
[patent_app_type] => utility
[patent_app_number] => 17/316034
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 924
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316034
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/316034 | Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection | May 9, 2021 | Issued |
Array
(
[id] => 17937010
[patent_doc_number] => 11471442
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Administration of gut-selective JAK3 inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/315898
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 12
[patent_no_of_words] => 14536
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315898 | Administration of gut-selective JAK3 inhibitor | May 9, 2021 | Issued |
Array
(
[id] => 18947014
[patent_doc_number] => 11890287
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Therapeutic compounds and compositions for treating social disorders and substance use disorders
[patent_app_type] => utility
[patent_app_number] => 17/314664
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 26350
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314664
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314664 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | May 6, 2021 | Issued |